Samsung Bioepis Puts Keytruda Biosimilar Into FDA Review With Full Phase 3 Lung Cancer Trial Data
One week after filing its first US drug application, Samsung Bioepis presented the clinical evidence that supports it — a complete Phase 3 dataset showing its Keytruda copy works as well as the original in a 555-patient lung cancer trial, the most detailed …